QR-koodi

Synergistic anticancer effects of camptothecin and sotorasib in KRAS-mutated pancreatic ductal adenocarcinoma

BackgroundSotorasib (AMG510) is a first-in-class irreversible, covalent, and selective KRAS G12C inhibitor. However, in patients, acquired clinical resistance was observed within 1 year of its FDA approval. Researchers are exploring combination and repurposing strategies to help overcome this resist...

Täydet tiedot

Tallennettuna:
Päätekijät: Prasanna Srinivasan Ramalingam, Gayathri Chellasamy, Md Sadique Hussain, Gothandam Kodiveri Muthukaliannan, Tajamul Hussain, Salman Alrokayan, Kyusik Yun, Janaki Ramaiah Mekala, Sivakumar Arumugam
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Frontiers Media S.A. 2025-07-01
Sarja:Frontiers in Pharmacology
Aiheet:
alkaloid
camptothecin
sotorasib
KRAS mutation
PDAC
synergistic effect
Linkit:https://www.frontiersin.org/articles/10.3389/fphar.2025.1635449/full
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia